We noted that the ARHGEF1 i.p. generated from lysates of breast-cancer PDX treated with cortactin siRNA had less capacity to generate activated RhoA than the ARHGEF1 i.p. of PDX treated with control, nonspecific siRNA (Supplementary Fig. 9d). This evidence concerns the gene RHOA and breast cancer.